参考文献/References:
[1] 汪汉 结缔组织疾病相关肺动脉高压的比较[J]. 心血管病学进展2017,38(6):700-703.
[2] 国家风湿病数据中心中国系统性红斑狼疮研究协作组. 中国成人系统性红斑狼疮相关肺动脉高压诊治共识[J]. 中华内科杂志2015,54(1):81-86.（同[17]重复？？？）
[3]彭方琴汪汉蔡琳.肺动脉高压合并心包积液[J]. 心血管病学进展2017,38(3):300-304.
[4] Xia YK,Tu SH,Hu YH,et al. Pulmonary hypertension in systemic lupus erythematosus:a systematic review and analysis of 642 cases in Chinese population[J]. Rheumatol Int ,2013,33(5):1211-1217.
[5] Sun L,Wang Y,Dong Y,et al. Assessment of right atrium function in patients with systemic lupus erythematosus with different pulmonary artery systolic pressures by 2-dimensional speckle-tracking echocardiography[J]. J Ultrasound Med,2018,37(10):2345-2351.
[6] Zhang N,Li M,Qian J,et al. Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study:baseline characteristics and risk factors[J]. Int J Rheum Dis,2019,22(5):921-928.
[7] Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus:current status and future direction[J]. Clin Dev Immunol,2012,2012:854941.
[8] Tselios K,Gladman DD,Harvey P,et al. Abnormal cardiac biomarkers in patients with systemic lupus erythematosus and no prior heart disease:a consequence of antimalarials? [J]. J Rheumatol,2019,46(1):64-69.
[9] Hachulla E,Jais X,Cinquetti G,et al. Pulmonary arterial hypertension associated with systemic lupus erythematosus:results from the French Pulmonary Hypertension Registry[J]. Chest,2018,153(1):143-151.
[10] 汪汉何春容. 系统性红斑狼疮相关肺动脉高压的流行病学及发病机制[J]. 心血管病学进展2019,40(4):514-516.
[11] Gonzalez-Lopez L,Cardona-Munoz EG,Celis A,et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus[J]. Lupus,2004,13(2):105-112.
[12] Hennigan S,Channick RN,Silverman GJ. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus:a case report[J]. Lupus,2008,17(8):754-756.
[13] Mok MY,Tsang PL,Lam YM,et al. Bosentan use in systemic lupus erythematosus patients with pulmonary arterial hypertension[J]. Lupus,2007,16(4):279-285.
[14] Badesch DB,Tapson VF,McGoon MD,et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease:a randomized,controlled trial[J]. Ann Intern Med,2000,132(6):425-434.
[15] Galiè N,Ghofrani HA,Torbicki A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension[J]. N Engl J Med,2005,353:2148-2157.
[16] Qian J,Li M,Zhang X,et al. Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension:CSTAR-PAH cohort study[J]. Eur Respir J,2019,53(2):pii:1800081.
[17]国家风湿病数据中心中国系统性红斑狼疮研究协作组. 中国成人系统性红斑狼疮相关肺动脉高压诊治共识[J]. 中华内科杂志2015,54(1):81-86.（同[2]重复？？？）
[18] Matsukawa Y,Igei K,Nozaki T,et al. Low-dose epoprostenol improved pulmonary hypertension in a patient with systemic lupus erythematosus[J]. Clin Rheumatol,2007,26(4):582-583.
[19] Molina J,Lucero E,Luluaga S,et al. Systemic lupus erythematosus-associated pulmonary hypertension:good outcome following sildenafil therapy[J]. Lupus,2003,12(4):321-323.
[20] Demir M,Akpinar O,Kocabas A,et al. Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report[J]. Clin Rheumatol,2005,24(6):671-672.
[21] Mu L,Hao Y,Fan Y,et al. Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus[J]. Lupus,2018,27(10):1742-1752.
[22] Qian J,Wang Y,Huang C,et al. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension:a PRISMA-compliant systematic review and meta-analysis[J]. Autoimmun Rev,2016,15(3):250-257.
[23] Castillo-Martínez D,Marroquín-Fabián E,Lozada-Navarro,AC,et al. Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus:a seven-year follow-up study[J]. Lupus,2016,25(1):61-66.
[24] Kim JS,Kim D,Joo YB,et al. Factors associated with development and mortality of pulmonary hypertension in systemic lupus erythematosus patients[J]. Lupus,2018,27(11):1769-1777.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(8):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(8):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(8):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(8):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[5]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[6]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[7]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[8]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(8):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[9]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
[10]刘雪鸢 徐燕萍 殷跃辉.交感神经去除术在肺动脉高压治疗中的研究进展[J].心血管病学进展,2020,(5):480.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.010]
LIU Xueyuan,XU Yanping,YIN Yuehui.Sympathetic Denervation in Treatment of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):480.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.010]